| PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression F Panet, F Couture, A Kwiatkowska, R Desjardins, B Guérin, R Day European journal of cell biology 96 (5), 469-475, 2017 | 24 | 2017 |
| Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases AM Lazaratos, SM Maritan, A Quaiattini, A Darlix, I Ratosa, E Ferraro, ... The Breast, 2023 | 8 | 2023 |
| Sustained response to the mitogen-activated extracellular kinase inhibitor trametinib in a spindle cell sarcoma harboring a QKI-RAF1 gene fusion F Panet, S Jung, T Alcindor JCO Precision Oncology 6, 2022 | 4 | 2022 |
| Predictors of nodal metastases in early stage HER2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery S Faleh, I Prakash, E Eisenberg, M Basik, JF Boileau, D Tejera, F Panet, ... European Journal of Surgical Oncology 49 (8), 1411-1416, 2023 | 3 | 2023 |
| The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature F Panet, M Tétreault‐Langlois, V Morin, K Sultanem, D Melnychuk, ... Cancer Reports 5 (7), e1531, 2022 | 3 | 2022 |
| Inflammatory response to the anti PD-L1 drug, atezolizumab, masquerades as breast implant rupture ME Marcotte, F Panet, E Croteau, MA Richard, M Pavic, MA Levasseur European Journal of Nuclear Medicine and Molecular Imaging 46, 2402-2403, 2019 | 1 | 2019 |
| Preoperative factors that predict pathologic nodal involvement in early-stage HER2+ breast cancer: selecting cT1cN0 patients for treatment with neoadjuvant chemotherapy versus … S Faleh, I Prakash, A Salehi, H Khan, M Basik, JF Boileau, D Tejera, ... Breast Cancer Research and Treatment, 1-10, 2024 | | 2024 |
| A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. AM Lazaratos, SM Maritan, A Darlix, I Ratosa, E Ferraro, G Griguolo, ... Journal of Clinical Oncology 41 (16_suppl), 2034-2034, 2023 | | 2023 |
| Abstract P2-01-06: Real-world outcome and cost analysis of the addition of pertuzumab to neoadjuvant therapy in localized HER2 positive breast cancer: a single center experience F Panet, M Young, S Wong, A Dragomir, AAN Rose, L Panasci Cancer Research 83 (5_Supplement), P2-01-06-P2-01-06, 2023 | | 2023 |
